Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $9.2650 (-12.1%) ($9.2650 - $9.2650) on Wed. Dec. 9, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.7% (three month average) | RSI | 43 | Latest Price | $9.2650(-12.1%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.4% a day on average for past five trading days. | Market Behavior | Growth stock sell-off for large cap. Growth stock sell-off for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) ARKG(13%) BNDX(13%) LIT(13%) SKYY(13%) XBI(13%) | Factors Impacting AUTL price | AUTL will decline at least -2.35% in a week (0% probabilities). TBT(-9%) USO(-7%) VIXM(-6%) UNG(-6%) XLF(-2%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.35% (StdDev 4.7%) | Hourly BBV | -0.4 () | Intraday Trend | 0% | | | |
|
Inflection Point | Yes | Resistance Level | $10.52 | 5 Day Moving Average | $10.55(-12.18%) | 10 Day Moving Average | $10.35(-10.48%) | 20 Day Moving Average | $10.52(-11.93%) | To recent high | -35.1% | To recent low | 0% | Market Cap | $484m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |